Free Trial
NASDAQ:GYRE

Gyre Therapeutics Q1 2025 Earnings Results & Report

Gyre Therapeutics logo
$4.74 +0.44 (+10.09%)
As of 01:06 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Gyre Therapeutics met analyst earnings expectations and missed on revenue in its Q1 2025 results, released May 9, 2025. The company reported EPS of $0.03 versus the $0.03 consensus estimate, while revenue of $22.06 million fell short of the $28.40 million estimate by $6.34 million.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens
Conference Call
6:00 AM ET

Gyre Therapeutics EPS Results

Actual EPS
$0.03
Consensus EPS
$0.03
Beat/Miss
Met Expectations
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 8 quarters

Gyre Therapeutics Revenue Results

Actual Revenue
$22.06 million
Expected Revenue
$28.40 million
Beat/Miss
Missed by -$6.34 million
YoY Revenue Growth
N/A

Gyre Therapeutics Q1 2025 Earnings FAQ

Gyre Therapeutics (NASDAQ:GYRE) reported earnings of $0.03 per share for Q1 2025, matching the consensus estimate of $0.03. The report was announced on Friday, May 9, 2025.

Gyre Therapeutics reported revenue of $22.06 million for Q1 2025, against a consensus estimate of $28.40 million.

Gyre Therapeutics Earnings Headlines

Why my scanner is $7
Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full year, with no re-bills and nothing to install. The catch? He isn't trying to profit on the scanner itself. Poulos is betting that once you see it deliver the night's list, you'll want more of his work for years.tc pixel
See More Gyre Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Gyre Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Gyre Therapeutics and other key companies, straight to your email.

About Gyre Therapeutics

Gyre Therapeutics (NASDAQ:GYRE) is a biopharmaceutical company focused on developing and commercializing treatments for liver and other chronic diseases. The company operates in the United States and China, including through its China-based subsidiary, Beijing Continent Pharmaceuticals.

Its pipeline includes hydronidone, also known as F351, an oral drug candidate being developed for liver fibrosis associated with chronic hepatitis B. Gyre is also developing treatments for other serious conditions, including acute-on-chronic liver failure.

The company adopted the Gyre Therapeutics name in 2023, following its predecessor Catalyst Biosciences’ acquisition of a majority stake in Gyre Pharmaceuticals. This brought together U.S.-based drug development activities and established pharmaceutical operations in China.

View Gyre Therapeutics Profile